Flamicort 40mg/ml injection

Dexa Medica

Ingredients in every ml

Triamcinolone 40 mg

Each package contains

1 vial of 1 ml

Other details

Dosage form:Injection
Flavour None

W.H.O. classification

ATC Level 1 H - Systemic hormonal preparations; excluding sex hormones and insulins
ATC Level 2 H02 - Corticosteroids for Systemic Use
ATC Level 3 H02A - Corticosteroids for Systemic Use; Plain

Warnings

Pregnancy

CONSULT YOUR DOCTORSafety of this item for use during pregnancy has not been established. Please consult your doctor.

Lactation

CONSULT YOUR DOCTORSafety of this item for use during lactation has not been established. Please consult your doctor.

Alcohol

CONSULT YOUR DOCTORSafety of this item for use with alcohol has not been established. Please consult your doctor.

Machinery

CONSULT YOUR DOCTORSafety of this item for use while operating heavy machinery has not been established. Please consult your doctor.

Available in

Indonesia

Dosage information

12 YEARS OLD AND ABOVE
Initial dose: 60 mg.
Dosage is usually adjusted within the range of 40-80 mg, depending upon patient’s response and duration of relief.

6 TO 12 YEARS OLD
Initial dose: 40 mg.
Dosage depends more on the severity of symptoms than on age or weight.

0 TO 6 YEARS OLD
Insufficient clinical experience.

GENERAL DOSE
2.5 to 60 mg per day, depending on the specific disease entity being treated. In situations of less severity, lower doses will generally suffice while in selected patients higher initial doses may be required.

MAINTENANCE DOSE
After a favorable response is noted, maintenance dosage must be determined by decreasing the initial drug dosage in small increments at appropriate time intervals until the lowest dosage which will maintain an adequate clinical response is reached.

Indication

Intramuscular
Where oral therapy is not feasible or is temporarily undesirable in the judgement of the physician, Flamicort injection 40 mg/ml is indicated for intramuscular use as follows:
1. Allergic diseases.
2. Rheumatic disorders
As adjunctive therapy for short-term administration (to tide the patient over an acute episode exacerbation) in: post-traumatic osteoarthritis, synovitis of osteoarthritis, rheumatoid arthritis, acute or sub-acute bursitis, epicondylitis, acute nonspecific tenosynovitis, acute gouty arthritis, psoriatic arthritis, ankylosing spondylitis, juvenile rheumatoid arthritis.
3. Collagen diseases
During an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus, acute rheumatic carditis.
4. Dermatologic diseases
Pemphigus, severe erythema multiforme (Stevens-Johnson syndrome), exfoliative dermatitis, bullous dermatitis herpetiformis, severe seborrheic dermatitis, severe psoriasis.
5. Edematous state
To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus.